Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2010 1
2011 2
2012 1
2013 1
2014 3
2015 6
2016 4
2017 7
2018 5
2019 5
2020 4
2021 10
2022 11
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Common and rare variant associations with clonal haematopoiesis phenotypes.
Kessler MD, Damask A, O'Keeffe S, Banerjee N, Li D, Watanabe K, Marketta A, Van Meter M, Semrau S, Horowitz J, Tang J, Kosmicki JA, Rajagopal VM, Zou Y, Houvras Y, Ghosh A, Gillies C, Mbatchou J, White RR, Verweij N, Bovijn J, Parikshak NN, LeBlanc MG, Jones M; Regeneron Genetics Center; GHS-RGC DiscovEHR Collaboration; Glass DJ, Lotta LA, Cantor MN, Atwal GS, Locke AE, Ferreira MAR, Deering R, Paulding C, Shuldiner AR, Thurston G, Ferrando AA, Salerno W, Reid JG, Overton JD, Marchini J, Kang HM, Baras A, Abecasis GR, Jorgenson E. Kessler MD, et al. Nature. 2022 Dec;612(7939):301-309. doi: 10.1038/s41586-022-05448-9. Epub 2022 Nov 30. Nature. 2022. PMID: 36450978 Free PMC article.
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Zhou X, Karantza V, Mejia J, Cortes J; KEYNOTE-119 investigators. Winer EP, et al. Lancet Oncol. 2021 Apr;22(4):499-511. doi: 10.1016/S1470-2045(20)30754-3. Epub 2021 Mar 4. Lancet Oncol. 2021. PMID: 33676601 Clinical Trial.
The most common grade 3-4 treatment-related adverse events were anaemia (three [1%] patients in the pembrolizumab group vs ten [3%] in the chemotherapy group), decreased white blood cells (one [<1%] vs 14 [5%]), decreased neutrophil count (one [<1%] vs 29 [10%]), and …
The most common grade 3-4 treatment-related adverse events were anaemia (three [1%] patients in the pembrolizumab group vs ten [3%] in the c …
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Tolaney SM, et al. J Clin Oncol. 2021 Aug 20;39(24):2720-2731. doi: 10.1200/JCO.20.03613. Epub 2021 May 18. J Clin Oncol. 2021. PMID: 34003702 Free PMC article.
White blood count, D-dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID-19 patients: The French multicenter CLOTVID retrospective study.
Galland J, Thoreau B, Delrue M, Neuwirth M, Stepanian A, Chauvin A, Dellal A, Nallet O, Roriz M, Devaux M, London J, Martin-Lecamp G, Froissart A, Arab N, Ferron B, Groff MH, Queyrel V, Lorut C, Regard L, Berthoux E, Bayer G, Comarmond C, Lioger B, Mekinian A, Szwebel TA, Sené T, Amador-Boreiro B, Mangin O, Sellier PO, Mouly S, Kevorkian JP, Siguret V; Lariboisière COVID Group; Vodovar D, Sene D. Galland J, et al. Eur J Haematol. 2021 Aug;107(2):190-201. doi: 10.1111/ejh.13638. Epub 2021 May 24. Eur J Haematol. 2021. PMID: 34288162 Free PMC article.
Based on CTPA, 47 (53.4%) patients were diagnosed with PE, and 41 were not. D-dimer 3000 ng/mL (OR 8.2 [95% CI] 1.3-74.2, sensitivity (Se) 0.84, specificity (Sp) 0.78, P = .03), white blood count (WBC) 12.0 G/L (29.5 [2.3-1221.2], Se 0.47, Sp 0.92, P = .02), and fer …
Based on CTPA, 47 (53.4%) patients were diagnosed with PE, and 41 were not. D-dimer 3000 ng/mL (OR 8.2 [95% CI] 1.3-74.2, sensitivity …
Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial.
Schwedt TJ, Myers Oakes TM, Martinez JM, Vargas BB, Pandey H, Pearlman EM, Richardson DR, Varnado OJ, Cobas Meyer M, Goadsby PJ. Schwedt TJ, et al. Neurol Ther. 2024 Feb;13(1):85-105. doi: 10.1007/s40120-023-00562-w. Epub 2023 Nov 10. Neurol Ther. 2024. PMID: 37948006 Free PMC article.
METHODS: In this 3-month, double-blind, double-dummy study, participants were randomized (1:1) to subcutaneous (SC) galcanezumab 120 mg per month (after a 240 mg loading dose) and a placebo oral disintegrating tablet (ODT) every other day (q.o.d.) or to rimegepant 75 mg OD …
METHODS: In this 3-month, double-blind, double-dummy study, participants were randomized (1:1) to subcutaneous (SC) galcanezumab 120 mg per …
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Lester DK, et al. Nat Cancer. 2023 Feb;4(2):222-239. doi: 10.1038/s43018-022-00506-7. Epub 2023 Jan 23. Nat Cancer. 2023. PMID: 36690875 Free PMC article.
[Ophthalmologic emergencies].
Tuil E, Kallel S. Tuil E, et al. Rev Prat. 2012 Nov;62(9):1247. Rev Prat. 2012. PMID: 23272477 French.
The issues addressed in this folder "ophthalmologic emergencies" include symptoms most frequently encountered in clinical practice (ocular trauma, decreased visual acuity, eye pain red or white or not); their knowledge by GPs is needed to better management of patient....
The issues addressed in this folder "ophthalmologic emergencies" include symptoms most frequently encountered in clinical practice (ocular t …
Projecting Quarantine Utilization During a Pandemic.
Li W, Kolaczyk ED, White LF. Li W, et al. Am J Public Health. 2022 Feb;112(2):277-283. doi: 10.2105/AJPH.2021.306573. Am J Public Health. 2022. PMID: 35080960 Free PMC article.
Global Dietary and Herbal Supplement Use during COVID-19-A Scoping Review.
Arora I, White S, Mathews R. Arora I, et al. Nutrients. 2023 Feb 2;15(3):771. doi: 10.3390/nu15030771. Nutrients. 2023. PMID: 36771480 Free PMC article. Review.
A systematic search was conducted in December 2021 following PRISMA guidelines. PubMed, ERIC, and Scopus databases were searched, and 956 results were screened for eligibility. ...All studies were large population surveys investigating healthy eating and supplement use dur …
A systematic search was conducted in December 2021 following PRISMA guidelines. PubMed, ERIC, and Scopus databases were searched, and …
67 results